Annovis Bio (NYSE:ANVS) announced the publication of three granted U.S. patents that cover methods of treating amyloid lateral sclerosis, Huntington’s disease, and prion diseases by administering buntanetap. The...
Fresh Tracks Therapeutics (NASDAQ:FRTX), formerly Brickell Biotech, initiated the multiple ascending dose (MAD) portion of the ongoing Phase 1 clinical trial in Canada, evaluating FRTX-02, its lead drug candidate, in...
Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first stage 3 (F3) NASH subject with rencofilstat in a Phase 2 clinical trial designed to measure hepatic function. The trial is being conducted in collaboration with...
POINT Biopharma Global (NASDAQ:PNT) published a poster at ESMO Congress 2022 containing updated efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the company’s Phase 3 SPLASH...
Vistagen Therapeutics (NASDAQ:VTGN) announced completion of an interim analysis of PALISADE-2, its second Phase 3 clinical trial assessing drug candidate, PH94B, as an acute treatment of anxiety in adults with social...
Patient enrollment in the IntelGenx (TSX:IGX; OTCQB:IGXT) ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) has reached the halfway mark. This...
Closely-held VoxNeuro, a software-as-a-medical-device brain (SaMD) health company, is collaborating with Boston University to launch two studies that will evaluate the company’s cognitive health assessment platform in...
Brickell Biotech (NASDAQ:BBI) changed its name to Fresh Tracks Therapeutics, with a new stock symbol, FRTX, effective at the NASDAQ opening on Sept. 8, 2022. The unveiling of the company’s rebranding reinforces...
The European Commission has expanded the marketing authorization for Rhythm Pharmaceuticals’ (NASDAQ:RYTM) IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically...
Hepion Pharmaceuticals (NASDAQ:HEPA) screened the first subject in its ASCEND-NASH clinical trial being conducted at up to 121 sites in seven countries, including 85 sites in the U.S. The Phase 2b, randomized, multi...